Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz Egypt Partners Up To Launch Rituximab Biosimilar

Projected Savings For NHL Estimated At 40%

Executive Summary

Sandoz’ operation in Egypt has banded together with the Egyptian Cancer Society to introduce the firm’s biosimilar to Roche’s Rituxan/MabThera, three years after Hikma in-licensed a rituximab biosimilar from Celltrion.

You may also be interested in...

Alvogen Prevails On US Zohydro ER Appeal

Two treatment patents protecting Persion’s Zohydro ER hydrocodone extended-release tablets until July 2033 are invalid as obvious, the US Court of Appeals for the Federal Circuit has confirmed in a victory for Alvogen. 

Sandoz drops rituximab after US seeks more data

Sandoz will not pursue biosimilar rituximab in the US, the company has announced, following a complete response letter (CRL) from the US Food and Drug Administration (FDA) earlier this year asking for more information on the candidate. The CRL – issued in May (Generics bulletin, 11 May 2018, page 1) – came despite the firm’s biosimilar rituximab already being approved in markets such as the European Union (EU), Japan and Australia.

Hikma gets rituximab in deal with Celltrion

Hikma Pharmaceuticals has reached its third biosimilar licensing agreement with Celltrion, acquiring exclusive rights to distribute and sell the South Korean firm’s Truxima (rituximab) biosimilar in the Middle East and North Africa (MENA).


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts